middl
east
respiratori
syndrom
coronaviru
merscov
first
identifi
pneumon
patient
subsequ
die
saudi
arabia
sinc
emerg
viru
infect
individu
outbreak
occur
mainli
arabian
peninsula
larg
crowd
hospit
one
larg
outbreak
republ
although
bat
propos
possibl
natur
reservoir
dromedari
camel
confirm
anim
host
far
half
human
primari
case
report
contact
index
patient
korean
outbreak
travel
back
gulf
countri
merscov
endem
circul
dromedari
sever
studi
camel
show
seropreval
rate
merscov
africa
arabian
mean
seropreval
higher
older
camel
juvenil
furthermor
dromedari
serum
sampl
collect
archiv
differ
countri
africa
arabia
test
posit
merscov
neutralis
antibodi
nab
moreov
recent
studi
saudi
arabia
show
n
dromedari
associ
confirm
human
case
seroposit
viral
rna
isol
importantli
sequenc
viral
rna
patient
camel
confirm
genet
similar
everi
pair
therefor
seem
clear
merscov
circul
dromedari
africa
arabia
past
three
decad
caus
human
infect
sinc
unlik
arabian
countri
report
human
case
africa
could
due
underdiagnosi
differ
camel
husbandri
practic
one
studi
recent
demonstr
viru
africa
may
genet
phenotyp
date
antivir
vaccin
treat
prevent
merscov
human
camel
camel
merscov
infect
mild
transient
requir
veterinari
care
therefor
littl
encourag
camel
owner
vaccin
anim
merscov
howev
increas
bodi
evid
asymptomat
mildli
symptomat
human
case
amongst
peopl
regularli
contact
camel
suggest
peopl
may
transmit
infect
therefor
success
vaccin
camel
would
reduc
viru
circul
anim
host
therebi
reduc
human
exposur
lead
reduct
number
human
case
addit
develop
vaccin
human
vaccin
human
risk
camel
keeper
health
care
worker
would
control
number
human
infect
prevent
spread
viru
gener
popul
vaccin
may
develop
use
camel
human
trimer
spike
glycoprotein
main
target
experiment
merscov
vaccin
play
integr
role
viral
entri
fusion
target
consist
receptorbind
domain
rbd
contain
subunit
bind
dipeptidyl
peptidas
target
cell
subunit
contain
fusion
peptid
involv
viral
fusion
target
sever
vaccin
candid
develop
test
multipl
anim
model
includ
mice
rabbit
nonhuman
primat
dromedari
review
mani
vaccin
design
base
fulllength
protein
other
target
subunit
rbd
protein
focu
immun
respons
critic
neutralis
epitop
induc
nab
nonetheless
nonneutralis
antibodi
ab
could
also
aid
protect
merscov
inhibit
essenti
step
viral
replic
virustarget
cell
fusion
furthermor
shown
nab
alon
could
confer
sterilis
immun
could
provid
partial
protect
camel
probabl
due
sever
factor
includ
wane
nab
genet
chang
viral
thu
develop
camel
vaccin
base
fulllength
protein
could
potenti
elicit
robust
antibodi
cell
respons
compar
shorter
target
develop
chimpanze
adenovir
vector
base
vaccin
merscov
mer
test
mous
model
efficaci
demonstr
efficaci
singl
mer
gener
insert
full
length
spike
gene
merscov
isol
genbank
access
number
genom
replic
defici
vector
describ
viral
vector
vaccin
replicationdefici
assess
differ
anim
model
includ
human
clinic
evalu
immunogen
efficaci
mer
dromedari
either
seroposit
seroneg
merscov
also
evalu
age
effect
vaccin
immunogen
seroneg
dromedari
calv
first
time
utilis
natur
infect
model
challeng
evalu
mer
vaccin
efficaci
camel
realworld
set
rather
singl
exposur
merscov
challeng
experi
conduct
within
biocontain
facil
also
first
studi
evalu
mer
vaccin
dromedari
endem
countri
twenti
calv
seroneg
seroposit
divid
four
group
n
group
seroneg
camel
receiv
control
inject
either
pb
n
encod
enhanc
green
fluoresc
protein
n
group
seroneg
camel
receiv
mer
vaccin
group
c
seroposit
camel
receiv
control
inject
either
pb
n
n
group
v
seroposit
camel
receiv
mer
vaccin
fig
tabl
serum
sampl
collect
day
prevaccin
day
post
immunis
dpi
addit
dpi
two
camel
group
boost
second
inject
mer
pb
respect
sampl
collect
day
post
boost
dpb
shown
fig
three
month
post
prime
ie
dpi
vaccin
camel
challeng
natur
infect
model
introduc
ten
natur
infect
viru
shed
camel
refer
infecti
camel
infecti
experiment
ratio
order
evalu
vaccin
efficaci
fig
merscov
test
nasal
swab
rtqpcr
day
post
challeng
dpc
dpc
camel
neg
merscov
infect
dpc
except
one
individu
camel
dpc
figur
serum
sampl
evalu
use
commerci
elisa
kit
figur
inhous
endpoint
titr
elisa
fig
seroneg
camel
group
ab
detect
two
camel
receiv
boost
vaccin
fig
ab
level
similar
titr
natur
infect
camel
howev
ab
titr
decreas
log
day
dpi
ie
time
challeng
fig
indic
gener
measur
antispik
ab
naiv
dromedari
vaccin
possibl
howev
ab
declin
three
month
vaccin
boost
strategi
consid
naiv
calv
convers
vaccin
seroposit
camel
mer
vaccin
group
v
enhanc
ab
titr
one
log
compar
group
c
three
month
post
vaccin
fig
c
although
group
similar
baselin
level
ab
dpi
time
challeng
group
higher
level
ab
compar
infecti
camel
fold
increas
ab
endpoint
titr
seroposit
camel
shown
fig
exposur
infecti
camel
ab
level
increas
group
except
v
group
highest
level
ab
prechalleng
overal
ab
level
group
plateau
nine
month
post
challeng
dpi
challeng
infect
substanti
differ
among
seroneg
camel
group
receiv
either
one
two
dose
vaccin
indic
smallrang
error
bar
ab
titr
group
post
challeng
data
dpi
fig
level
nab
detect
pseudotyp
viru
neutralis
assay
merspp
na
dpi
shown
fig
group
seroposit
prior
vaccin
c
v
nab
day
signific
differ
two
group
vaccin
increas
titr
dpi
howev
titr
vaccin
group
v
maintain
level
day
unlik
nonvaccin
camel
show
decreas
nab
titr
dpi
ten
infecti
camel
merscov
natur
infect
viral
shed
camel
confirm
posit
merscov
rtqpcr
ct
valu
figur
cohous
experiment
calv
vaccin
experi
one
pen
start
dpi
fig
result
total
camel
pen
arbitrari
indic
infect
nasal
discharg
camel
group
evalu
score
normal
sever
explain
method
depend
discharg
abund
dpc
figur
area
curv
auc
score
plot
fig
camel
seroposit
vaccin
v
control
c
group
mild
nasal
discharg
resolv
day
post
challeng
respect
figur
three
camel
seroposit
group
sever
nasal
discharg
last
one
two
day
seroneg
group
show
nasal
discharg
persist
two
week
overal
vaccin
seroposit
seroneg
camel
reduc
nasal
discharg
time
significantli
compar
control
camel
p
analys
mix
model
analysi
group
vaccin
effect
reduc
nasal
discharg
substanti
differ
primeboost
vaccin
camel
camel
number
primeonli
vaccin
camel
figur
area
curv
auc
nasal
discharg
score
also
plot
show
overal
reduct
score
vaccin
camel
compar
control
camel
seroposit
vaccin
camel
signific
overal
reduct
nasal
discharg
p
fig
nasal
swab
camel
collect
daili
day
follow
introduct
infecti
camel
challeng
day
post
challeng
interestingli
total
number
infecti
viru
shed
camel
pen
increas
challeng
studi
vari
week
post
challeng
figur
seroneg
control
camel
well
camel
group
infect
earli
number
viru
shed
camel
peak
camel
second
day
post
challeng
result
high
viral
exposur
uninfect
camel
number
infect
camel
remain
first
week
start
declin
second
week
post
challeng
figur
viral
shed
evalu
test
merscov
rna
evalu
viral
titr
post
challeng
nasal
swab
use
rtqpcr
fig
group
viral
rna
decreas
undetect
level
post
challeng
figur
seroneg
vaccin
control
camel
shed
high
level
viru
start
day
postchalleng
contrari
seroposit
camel
c
v
shed
low
level
viru
post
challeng
fig
note
vaccin
seroneg
seroposit
camel
v
higher
viru
titr
day
post
challeng
compar
control
seroneg
seroposit
camel
c
howev
viru
titr
vaccin
camel
v
group
rapidli
decreas
time
compar
control
camel
c
fig
infecti
camel
high
titr
viral
rna
start
day
challeng
day
measur
hous
studi
camel
declin
time
figur
signific
differ
viral
shed
seroneg
camel
receiv
singl
two
dose
mer
seen
small
rang
error
bar
data
group
fig
despit
camel
receiv
primeboost
immunis
signific
level
ab
target
main
antigen
facilit
viral
entri
vaccin
intervent
time
analys
vaccin
effect
viru
titr
day
statist
signific
p
vaccin
camel
v
group
analys
mix
model
analysi
shown
lower
viral
shed
vaccin
camel
compar
control
especi
seroposit
camel
fig
area
curv
auc
averag
viru
titr
group
also
report
fig
separ
attempt
evalu
effect
age
vaccin
immunogen
dromedari
calv
nine
seroneg
calv
vaccin
n
separ
studi
group
act
control
group
calv
younger
one
year
receiv
pb
n
n
group
calv
younger
one
year
receiv
singl
dose
mer
group
calv
age
one
two
year
receiv
singl
dose
mer
serum
sampl
collect
day
prevaccin
dpi
nasal
swab
also
collect
dpi
detect
ab
induc
younger
calv
group
except
one
camel
low
level
ab
wherea
ab
detect
older
calv
group
fig
similarli
circulatori
local
nab
induc
older
clave
group
group
fig
interestingli
pseudotyp
viru
neutralis
assay
merspp
na
correl
significantli
merscov
neutralis
assay
p
fig
appli
sera
subsequ
vaccin
initi
sampl
calv
age
group
studi
kept
serolog
follow
pen
separ
pen
away
pen
main
studi
perform
natur
challeng
unexpectedli
calv
age
group
studi
includ
control
calv
demonstr
immun
respons
assess
two
elisa
figur
b
dpi
overlap
time
natur
infect
challeng
main
studi
whilst
calv
test
merscov
rna
find
indic
calv
infect
challeng
studi
took
place
pen
away
strongli
exclud
possibl
mechan
transfer
viru
due
strict
adher
staff
infect
control
measur
monitor
surveil
camera
viru
transmiss
circul
calv
air
could
possibl
note
two
elisa
significantli
correl
figur
studi
demonstr
boost
humor
immun
respons
merscov
seroposit
camel
requir
singl
intramuscular
dose
mer
wherea
least
two
dose
vaccin
requir
induc
ab
young
seroneg
camel
year
interestingli
older
seroneg
calv
year
respond
singl
dose
vaccin
elicit
system
local
nab
histori
merscov
exposur
camel
known
possibl
older
camel
found
seroneg
may
natur
exposur
merscov
ab
declin
prior
inclus
studi
report
nonetheless
also
possibl
seroneg
calv
truli
immun
naiv
merscov
greater
vaccin
respons
occur
older
anim
matur
immun
system
unlik
matern
ab
play
part
lack
vaccin
respons
younger
calv
mer
viral
vector
vaccin
express
mer
protein
virion
surfac
affect
preexist
ab
time
vaccin
vaccin
result
statist
signific
reduct
viru
shed
cohous
infecti
camel
seroposit
seroneg
camel
wherea
viru
shed
minim
seroposit
vaccin
camel
optimis
requir
enhanc
protect
seroneg
camel
includ
number
dose
rout
immunis
inde
assess
abil
mvavector
merscov
vaccin
protect
camel
contain
merscov
challeng
requir
administ
multipl
dose
intramuscular
intranas
rout
significantli
reduc
viru
therefor
protect
effect
vaccin
administ
either
intranas
intramuscular
rout
assess
note
show
older
seroneg
camel
nab
nasal
secret
induc
singl
intramuscular
vaccin
mer
rule
possibl
camel
previous
expos
merscov
despit
prove
seroneg
entri
studi
effect
intramuscular
boost
initi
mucos
prime
may
differ
intramuscular
prime
truli
mersnaiv
camel
mechan
vaccinemedi
natur
acquir
protect
merscov
camel
yet
known
work
requir
studi
cell
respons
well
possibl
contribut
immun
antigen
protein
howev
lack
commerci
avail
dromedari
antibodi
immun
cell
marker
make
cell
immun
camel
difficult
assess
appropri
natur
challeng
model
employ
replic
close
condit
found
camel
herd
result
high
level
viru
exposur
mani
day
infecti
camel
remov
pen
cohous
mimic
natur
condit
even
stringent
condit
one
camel
group
v
demonstr
complet
absenc
viru
shed
two
other
total
group
shed
extrem
low
level
viru
indic
high
level
protect
immun
achiev
importantli
group
high
level
nab
plateau
year
unlik
c
group
decreas
nab
titr
overtim
result
suggest
vaccin
seroposit
camel
sbase
vaccin
could
boost
preexist
mersspecif
immun
minimis
viral
shed
nonetheless
follow
singl
dose
vaccin
viru
shed
reduc
seroposit
seroneg
camel
would
reduc
likelihood
transmiss
camel
human
previou
work
well
shown
excel
correl
pseudotyp
live
viru
neutral
thu
expect
nab
detect
merspp
neutral
assay
bind
rbd
close
bind
site
manner
block
bind
cellular
receptor
although
bind
site
nab
detect
pseudotyp
viru
neutral
assay
determin
per
se
nonetheless
nonneutralis
sspecif
ab
could
also
interfer
merscov
entri
fusion
similar
manner
stemspecif
antiinfluenza
hemagglutinin
yet
assess
merscov
similarli
elisa
shown
excel
correl
live
viru
neutral
assay
although
nab
well
nonneutralis
bind
ab
could
detect
current
studi
found
induct
nonneutralis
ab
alon
insuffici
reduc
viral
shed
presenc
nab
minimis
viru
excret
nonetheless
previou
studi
suggest
presenc
high
level
nab
titr
may
provid
sterilis
immun
dromedari
even
seroposit
camel
could
reinfect
nab
wane
studi
also
clearli
confirm
merscov
reinfect
occur
dromedari
note
nasal
discharg
follow
infect
observ
experiment
set
market
infecti
camel
purchas
may
use
reliabl
indic
infect
support
also
previou
viru
shed
continu
day
indic
averag
time
cours
mer
infect
penhous
camel
notabl
although
seroneg
younger
calv
respond
high
level
ab
primeboost
mention
show
signific
differ
nasal
discharg
viru
titr
compar
primeonli
seroneg
younger
calv
group
indic
induc
protect
immunogen
seroneg
calv
need
stringent
optim
vaccin
regimen
longrang
airborn
transmiss
viru
camel
hous
separ
manag
strict
infect
control
measur
also
demonstr
case
korean
hospit
accordingli
prevent
transmiss
camel
whenev
larg
group
anim
present
market
larg
herd
festiv
prevent
hygien
measur
vaccin
camel
introduc
minimis
transmiss
camel
human
studi
also
present
signific
correl
inhous
elisa
commerci
avail
elisa
kit
although
low
level
antibodi
sampl
detect
inhous
elisa
previou
report
show
commerci
elisa
kit
may
low
camel
research
farm
set
km
riyadh
citi
remot
urban
area
doubl
fenc
secur
gate
insid
farm
three
metal
pen
set
size
pen
cm
height
infect
control
entri
exit
point
away
pen
two
surveil
camera
instal
pen
food
water
trough
place
insid
pen
fill
outsid
without
enter
pen
supplementari
file
show
farm
layout
nineteen
seroneg
camel
calv
neg
elisa
sourc
purchas
jouf
provinc
north
saudi
arabia
transport
km
use
disinfect
lorri
research
farm
addit
ten
seroposit
merscov
rtpcr
neg
camel
calv
purchas
camel
market
riyadh
ten
seroneg
seroposit
calv
use
main
studi
wherea
remain
nine
seroneg
calv
use
small
follow
studi
determin
age
effect
addit
ten
activ
merscov
sheddinginfect
camel
posit
rtpcr
ct
valu
purchas
local
market
cohous
experiment
calv
one
pen
serv
natur
infect
model
challeng
overal
separ
pen
use
two
studi
third
pen
briefli
use
gather
infecti
viral
shed
camel
one
day
challeng
camel
label
paint
well
digit
microchip
two
label
use
sampl
ensur
accuraci
pen
keeper
veterinarian
driver
train
infect
control
practic
includ
fittest
mask
worker
use
specif
mask
overal
white
gown
goggl
head
cover
shoe
cover
dispos
use
team
adher
utilis
entri
exit
point
pen
ensur
infect
control
pen
don
dof
area
biohazard
wast
contain
sharp
biohazard
contain
ethanol
spray
virucid
aniospray
laboratoir
anio
franc
use
worker
staff
involv
studi
also
screen
confirm
merscov
neg
elisa
pcr
prior
end
studi
biowast
collect
daili
sent
inciner
saudi
gulf
environment
protect
compani
sepco
clean
sand
nearbi
dune
area
use
pen
floor
new
sand
ad
everi
month
pesticid
spray
pen
floor
start
studi
new
sand
ad
research
farm
pen
monitor
surveil
camera
ensur
strict
adher
infect
control
measur
ensur
camel
expos
stray
anim
eg
fox
dog
photograph
studi
includ
supplementari
file
mer
vaccin
candid
vector
control
produc
jenner
institut
univers
oxford
uk
previous
vaccin
vector
control
transfer
coldchain
deliveri
kaimrc
riyadh
saudi
arabia
thaw
ice
dose
prepar
second
time
minut
inject
singl
dose
infecti
unit
iu
either
vaccin
vector
control
ml
pb
per
camel
given
intramuscularli
thigh
muscl
camel
control
group
studi
group
c
camel
either
immunis
vector
control
pb
placebo
control
blood
sampl
collect
differ
dpi
transfer
lab
portabl
refriger
serum
ml
blood
camel
collect
time
point
blood
left
clot
hr
spun
rpm
min
serum
collect
aliquot
store
test
nasal
swab
camel
collect
viru
transport
media
vtm
store
test
serum
sampl
screen
elisa
use
camel
merscov
euroimmun
elisa
kit
euroimmun
germani
accord
manufactur
instruct
readout
report
ratio
sampl
optometr
densiti
od
od
intern
calibr
ratio
assign
posit
borderlin
respect
posit
neg
control
provid
kit
alway
includ
run
endpoint
titr
serum
ab
also
determin
use
inhous
indirect
elisa
previous
briefli
nunc
elisa
plate
thermo
scientif
usa
coat
recombin
protein
ivi
seoul
korea
overnight
wash
block
h
serum
sampl
ad
duplic
serial
dilut
start
h
incub
alkalin
phosphataseconjug
rabbit
antillama
igg
agrisera
usa
ad
dilut
final
pnitrophenyl
phosphat
substrat
pnpp
sigma
aldrich
germani
use
colour
develop
od
measur
nm
endpoint
titr
test
serum
determin
reciproc
valu
serum
dilut
od
valu
converg
cutoff
determin
averag
od
seroneg
camel
serum
plu
sd
describ
previous
fold
increas
ab
titr
calcul
divid
titr
time
point
titr
camel
day
prevaccin
titr
dpi
mer
pseudotyp
viral
particl
merspp
produc
titrat
use
cell
describ
heatinactiv
camel
serum
sampl
nasal
swab
vtm
prepar
serial
dilut
start
test
nab
duplic
describ
standard
concentr
merspp
equival
rlu
cell
cell
ad
well
cell
cell
merspp
without
serum
includ
quadrupl
control
determin
neutralis
activ
respect
follow
h
incub
cell
lyse
assay
develop
use
luciferas
assay
system
promega
usa
luciferas
activ
measur
use
luminomet
neutralis
titr
calcul
serum
sampl
use
graphpad
prism
experi
perform
twice
independ
background
signal
valu
nonspecif
neutralisi
sera
seroneg
camel
prevaccin
sampl
group
dpi
subtract
valu
sampl
group
c
v
well
viru
neutralis
assay
perform
previous
describ
induct
viru
nab
confirm
accord
previous
publish
briefli
heatinactiv
camel
serum
sampl
test
capac
neutralis
merscov
isol
infect
vitro
nab
titr
determin
reciproc
highest
dilut
complet
protect
cell
test
well
arbitrari
measur
evalu
camel
mer
infect
nasal
discharg
camel
group
observ
daili
given
score
discharg
abund
sever
score
normal
healthi
look
camel
camel
recov
nasal
discharg
littl
remain
dri
discharg
mild
nasal
secret
moder
nasal
secret
sever
nasal
secret
two
vet
assign
document
score
also
utilis
camel
nasal
photograph
taken
first
three
day
post
challeng
viral
rna
extract
nasal
swab
use
magna
pure
dna
viral
na
small
volum
kit
roch
diagnost
usa
extract
rna
sampl
test
use
one
step
rtpcr
target
merscov
upe
gene
previous
lightcycl
roch
diagnost
usa
sampl
consid
posit
upe
amplicon
detect
ct
valu
ct
valu
upe
gene
report
genom
equival
ge
titr
tissu
cultur
infecti
dose
per
ml
merscov
ge
isol
cultur
titrat
vero
cell
use
extract
viral
rna
viral
rna
serial
dilut
dilut
factor
dilut
use
synthesis
cdna
camel
nasal
swab
vtm
also
use
extract
total
rna
synthesi
cdna
cdna
sampl
use
primer
probe
previous
set
standard
curv
use
taqman
master
mix
abi
fast
realtim
pcr
system
appli
biosystem
usa
cutoff
assay
determin
base
last
dilut
plateau
standard
curv
cultur
viral
rna
neg
nasal
swab
sampl
healthi
human
healthi
camel
use
confirm
cutoff
shown
figur
statist
analys
perform
analys
chang
viru
titr
well
nasal
discharg
score
time
post
infect
challeng
first
mix
model
repeat
measur
design
logtransform
merscov
ge
valu
employ
account
covari
among
repeat
measur
assess
chang
viru
titr
time
viru
titr
anim
subject
measur
daili
equal
space
time
point
withinsubject
associ
among
repeat
measur
model
assum
firstord
autoregress
correl
structur
matrix
analysi
model
also
appli
nasal
discharg
score
collect
time
day
post
challeng
next
area
curv
auc
logtransform
merscov
ge
valu
nasal
discharg
score
collect
dpc
two
experiment
group
vaccin
control
across
two
condit
seroposit
statu
seroposit
seroneg
report
analysi
conduct
display
whether
differ
viru
titr
nasal
discharg
score
group
also
includ
cohen
test
standardis
measur
effect
size
ensur
suitabl
studi
sampl
size
statist
test
perform
see
supplementari
statist
file
statist
test
analysi
conduct
use
sa
sa
institut
inc
cari
nc
usa
graphpad
prism
softwar
studi
approv
institut
anim
care
use
committe
iacuc
king
abdullah
intern
medic
research
center
kaimrc
saudi
ministri
nation
guard
health
affair
mngha
anim
studi
conduct
supervis
saudi
ministri
environ
water
agricultur
mewa
accord
regul
law
ethic
research
live
creatur
set
monitor
saudi
nation
committe
bioethic
ncbe
